Journal
JOURNAL OF DRUG TARGETING
Volume 27, Issue 1, Pages 1-11Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2018.1455841
Keywords
RGD; integrin alpha(v)beta(3); non-viral vector; targeted gene delivery; cancer therapy
Categories
Ask authors/readers for more resources
Integrin alpha(v)beta(3) is restrictedly expressed on angiogenic blood vessels and tumour cells. It plays a key role in angiogenesis for tumour growth and metastasis. RGD peptide can specifically recognise the integrin alpha(v)beta(3), which serves as targeted molecular for anti-angiogenesis strategies. Therefore, the targeted delivery of therapeutics by RGD peptide-based non-viral vectors to tumour vasculature and tumour cells is recognised as a promising approach for treating cancer. In this review, we illustrate the interaction between RGD peptide and integrin alpha(v)beta(3) from different perspectives. Meanwhile, four types of RGD peptide-based non-viral gene delivery vectors for cancer therapy, including RGD-based cationic polymers, lipids, peptides and hybrid systems, are summarised. The aim is to particularly highlight the enhanced therapeutic effects and specific targeting ability exhibited by these vectors for cancer gene therapy both in vitro and in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available